EXEL Quote, Financials, Valuation and Earnings

Lineage Cell Therapeutics has a net margin of 28.74% compared to Exelixis's net margin of -275.57%. Exelixis's return on equity of 29.53% beat Lineage Cell Therapeutics's return on equity of -22.68%.

Exelixis has a consensus price target of $45.89, signalling upside risk potential of 2.42%. On the other hand Lineage Cell Therapeutics has an analysts' consensus of $3.92 which suggests that it could grow by 283.99%. Given that Lineage Cell Therapeutics has higher upside potential than Exelixis, analysts believe Lineage Cell Therapeutics is more attractive than Exelixis.

Exelixis has a beta of 0.283, which suggesting that the stock is 71.722% less volatile than S&P 500. In comparison Lineage Cell Therapeutics has a beta of 1.603, suggesting its more volatile than the S&P 500 by 60.322%.

Exelixis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lineage Cell Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exelixis pays -- of its earnings as a dividend. Lineage Cell Therapeutics pays out -- of its earnings as a dividend.

Exelixis quarterly revenues are $555.4M, which are larger than Lineage Cell Therapeutics quarterly revenues of $1.5M. Exelixis's net income of $159.6M is higher than Lineage Cell Therapeutics's net income of -$4.1M. Notably, Exelixis's price-to-earnings ratio is 20.37x while Lineage Cell Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis is 5.69x versus 22.52x for Lineage Cell Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 28.74% compared to Exelixis's net margin of 32.71%. Exelixis's return on equity of 29.53% beat Merck &'s return on equity of 39.02%.

Exelixis has a consensus price target of $45.89, signalling upside risk potential of 2.42%. On the other hand Merck & has an analysts' consensus of $101.79 which suggests that it could grow by 23.48%. Given that Merck & has higher upside potential than Exelixis, analysts believe Merck & is more attractive than Exelixis.

Exelixis has a beta of 0.283, which suggesting that the stock is 71.722% less volatile than S&P 500. In comparison Merck & has a beta of 0.389, suggesting its less volatile than the S&P 500 by 61.063%.

Exelixis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.88% to investors and pays a quarterly dividend of $0.81 per share. Exelixis pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Exelixis quarterly revenues are $555.4M, which are smaller than Merck & quarterly revenues of $15.5B. Exelixis's net income of $159.6M is lower than Merck &'s net income of $5.1B. Notably, Exelixis's price-to-earnings ratio is 20.37x while Merck &'s PE ratio is 12.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis is 5.69x versus 3.27x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Puma Biotechnology has a net margin of 28.74% compared to Exelixis's net margin of 6.46%. Exelixis's return on equity of 29.53% beat Puma Biotechnology's return on equity of 52.9%.

Exelixis has a consensus price target of $45.89, signalling upside risk potential of 2.42%. On the other hand Puma Biotechnology has an analysts' consensus of $3.00 which suggests that it could fall by -12.79%. Given that Exelixis has higher upside potential than Puma Biotechnology, analysts believe Exelixis is more attractive than Puma Biotechnology.

Exelixis has a beta of 0.283, which suggesting that the stock is 71.722% less volatile than S&P 500. In comparison Puma Biotechnology has a beta of 1.287, suggesting its more volatile than the S&P 500 by 28.736%.

Exelixis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Puma Biotechnology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exelixis pays -- of its earnings as a dividend. Puma Biotechnology pays out -- of its earnings as a dividend.

Exelixis quarterly revenues are $555.4M, which are larger than Puma Biotechnology quarterly revenues of $46M. Exelixis's net income of $159.6M is higher than Puma Biotechnology's net income of $3M. Notably, Exelixis's price-to-earnings ratio is 20.37x while Puma Biotechnology's PE ratio is 4.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis is 5.69x versus 0.73x for Puma Biotechnology. Usually stocks with elevated PS ratios are considered overvalued.

Spero Therapeutics has a net margin of 28.74% compared to Exelixis's net margin of -271.3%. Exelixis's return on equity of 29.53% beat Spero Therapeutics's return on equity of -108.26%.

Exelixis has a consensus price target of $45.89, signalling upside risk potential of 2.42%. On the other hand Spero Therapeutics has an analysts' consensus of $5.00 which suggests that it could grow by 102.43%. Given that Spero Therapeutics has higher upside potential than Exelixis, analysts believe Spero Therapeutics is more attractive than Exelixis.

Exelixis has a beta of 0.283, which suggesting that the stock is 71.722% less volatile than S&P 500. In comparison Spero Therapeutics has a beta of 1.331, suggesting its more volatile than the S&P 500 by 33.062%.

Exelixis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exelixis pays -- of its earnings as a dividend. Spero Therapeutics pays out -- of its earnings as a dividend.

Exelixis quarterly revenues are $555.4M, which are larger than Spero Therapeutics quarterly revenues of $5.1M. Exelixis's net income of $159.6M is higher than Spero Therapeutics's net income of -$13.9M. Notably, Exelixis's price-to-earnings ratio is 20.37x while Spero Therapeutics's PE ratio is 10.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis is 5.69x versus 4.76x for Spero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.